Press release
Hepatocellular Carcinoma Pipeline 2024 | Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma
Key Takeaways from the Hepatocellular Carcinoma Pipeline Report
* DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
* The leading companies working in the Hepatocellular Carcinoma Market include Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.
* Promising Hepatocellular Carcinoma Pipeline Therapies in the various stages of development include lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others.
Request a sample and discover the recent advances in Hepatocellular Carcinoma Treatment Drugs @ Hepatocellular Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
In the Hepatocellular Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hepatocellular Carcinoma Overview
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Cirrhosis is a significant step in viral carcinogenesis for hepatocellular carcinoma. Integration of the hepatitis B virus genome into the host genome is the primary pathogenesis for oncogenesis in HBV.
Find out more about Hepatocellular Carcinoma Treatment Landscape @ Drugs for Hepatocellular Carcinoma Treatment [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hepatocellular Carcinoma Emerging Drugs Profile
* Namodenoson: Can-Fite BioPharma
* SRF388: Surface Oncology
* Porustobart: Harbour BioMed
* Fisogatinib: CStone Pharmaceuticals
* STP705: Sirnaomics
Hepatocellular Carcinoma Pipeline Therapeutics Assessment
There are approx. 90+ key Hepatocellular Carcinoma companies which are developing the therapies for Hepatocellular Carcinoma. The Hepatocellular Carcinoma companies which have their Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Can-Fite BioPharma.
DelveInsight's Hepatocellular Carcinoma Pipeline Report covers around 95+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Hepatocellular Carcinoma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Learn more about the emerging Hepatocellular Carcinoma Pipeline Therapies @ Hepatocellular Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hepatocellular Carcinoma Pipeline Report
* Coverage- Global
* Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.
* Hepatocellular Carcinoma Pipeline Therapies- lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others.
Dive deep into rich insights for new drugs for Hepatocellular Carcinoma Treatment, Visit @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Hepatocellular Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hepatocellular Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Namodenoson: Can-Fite BioPharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SRF388: Surface Oncology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* STP705: Sirnaomics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Hepatocellular Carcinoma Key Companies
* Hepatocellular Carcinoma Key Products
* Hepatocellular Carcinoma- Unmet Needs
* Hepatocellular Carcinoma- Market Drivers and Barriers
* Hepatocellular Carcinoma- Future Perspectives and Conclusion
* Hepatocellular Carcinoma Analyst Views
* Hepatocellular Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatocellular-carcinoma-pipeline-2024-canfite-biopharma-sinocelltech-aveo-oncology-oxford-biotherapeutics-beijing-syngentech-surface-oncology-novartis-oncology-array-biopharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatocellular Carcinoma Pipeline 2024 | Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma here
News-ID: 3577574 • Views: …
More Releases from ABNewswire
To Close Construction's "Experience Gap," Veteran PE Roman Titov Mentors Next-Ge …
To combat the construction industry's "experience gap," veteran leader Roman Titov, P.E. (formerly of AWS & Jacobs), is mentoring the next generation of engineers. Through his courses at PDH-Pro, Titov shares practical, real-world project management wisdom to prepare future leaders for on-the-job challenges, bridging the gap between textbook theory and reality.
WELLESLEY, Mass. - Sept. 22, 2025 - As a generation of senior construction professionals prepares for retirement, a critical "experience…
Burna Boy Concert Tickets on a Budget: Lowest Prices with CITY10 Discount at Cap …
Catch Burna Boy live without breaking the bank! CapitalCityTickets.com offers the lowest prices on Burna Boy concert tickets. Use promo code CITY10 for extra savings and secure your spot at his electrifying shows. Don't miss out on the Afrobeat sensation-grab affordable tickets today and experience an unforgettable night of music and energy!
Are you a Burna Boy fan itching to catch the Afrobeat king live without draining your wallet? With his…
Best Deals on Jeff Dunham Live Shows: Low Prices Using Promo Code CITY10 via Cap …
Score big savings on Jeff Dunham live shows with CapitalCityTickets.com! Fans can find the best deals on tickets to see the world-famous ventriloquist and comedian live on stage. With promo code CITY10, enjoy an extra 10% off already low-priced tickets. Don't miss your chance to catch Dunham and his hilarious cast of characters on tour while saving money. Secure your Jeff Dunham tickets today and experience a night of nonstop…
Small Business, Big Relief: CopperJoint Highlights Family Roots with New Compres …
As a small, family-run business based in the U.S., CopperJoint blends heart and science in every product. The new compression socks for women and men combine a modern look with doctor-approved compression and all-day support - ideal for healthcare workers, professionals, and active adults. "We may be small, but our impact is felt every time a customer says, 'I can move without pain again.'"
NASHVILLE, TN - September 21, 2025 -…
More Releases for Hepatocellular
Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market Indust …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hepatocellular Carcinoma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for drugs used in hepatocellular carcinoma has seen significant expansion in the past few years. The market, which is predicted to rise from $1.16 billion in 2024 to $1.27 billion in…
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular …
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period?
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025…
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent…
Hepatocellular Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hepatocellular…
Hepatocellular Carcinoma Market - Winning the Battle Against Hepatocellular: Bre …
Newark, New Castle, USA: The "Hepatocellular Carcinoma Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hepatocellular Carcinoma Market: https://www.growthplusreports.com/report/hepatocellular-carcinoma-market/8027
This latest report researches the industry structure, sales, revenue,…
Hepatocellular Carcinoma Market Insights, Forecast to 2030
The report extensively examines the global Hepatocellular Carcinoma market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hepatocellular Carcinoma . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
